Myelodysplastic syndrome (MDS)

Myelodysplastic syndrome (MDS) is a condition where there is a disruption in the process of producing blood cells in the bone marrow, leading to a low number of blood cells circulating in the body. MDS primarily causes reduction in three types of blood cells: red blood cells, white blood cells, and platelets. Anemia occurs due to a lack of red blood cells, resulting in the need for frequent blood transfusions. Patients with reduced white blood cells become more susceptible to infections, and low platelet counts can result in bleeding.

The exact cause of MDS is still unknown, but chromosomal defects are found in the bone marrow cells of almost all patients. These genetic variations disrupt the normal growth of cells, contributing to the development of MDS.

Typically, MDS is diagnosed in people above the age of 50, with the average age of patients being around 70. The incidence of MDS increases with age, and after the age of 70, approximately 20 out of every 100,000 individuals develop this disease.

Over time, MDS can progress to Acute Myeloid Leukemia (AML), a form of blood cancer, which significantly reduces the patient's life expectancy.

MDS is classified into different types based on the specific blood cell deficiencies, the number of blast cells in the bone marrow, and other characteristics. The types of MDS include Refractory Anemia, Refractory Anemia with Ringed Sideroblasts, Refractory Cytopenia with Ringed Sideroblasts, MDS with Excess of Blasts-1, MDS with Excess of Blasts-2, and MDS with Isolated del(5q).

A bone marrow study is the only definitive way to diagnose MDS. Microscopic examination of the bone marrow reveals abnormal cell shapes, a finding known as dysplasia. Additionally, studying the chromosomes in the bone marrow cells is essential for accurate diagnosis. As dysplasia can also occur in other diseases, further tests are necessary to rule out alternative conditions.

The IPSS (International Prognostic Scoring System) score is a crucial factor in determining the treatment approach for each patient with MDS. This score is based on the type of MDS and the results of chromosomal studies, and it helps to estimate the average life expectancy of the patient. Unfortunately, for most types of MDS patients, if untreated or unresponsive to treatment, the average life expectancy is less than two years.

The IPSS score plays a vital role in guiding treatment decisions. For patients with low IPSS and only anemia present, Erythropoietin injections may be given. The drug Lenalidomide is highly effective for MDS caused by a specific chromosomal defect called Del 5q. In cases where these drugs do not provide the desired benefit or

for those with high IPSS, injections of Decitabine or Azacytidine are given. Each treatment cycle is typically 28 days, with injections administered for three to seven days. After six cycles, the treatment's effectiveness is evaluated. If good response is observed, the cycles of injections needs to be continued. However, if no benefit is seen after six cycles, treatment with these injections is stopped, and supportive care is provided, which includes blood transfusions and antibiotics for infections as needed.

If there is a good response after six cycles, two treatment paths are available. One option is to continue the cycles without interruption. Although this approach can extend the disease-free period for a few years, eventually, MDS may return, and only supportive care may be possible.

The second option is Bone Marrow Transplantation, a potentially curative treatment method. However, it is risky, particularly for very old patients, as adverse effects can be significant and may lead to death. Bone Marrow Transplantation requires careful consideration of the patient's overall health condition, mental strength, and other factors. While it can cure the disease completely, survivors may experience challenging side effects such as Graft-versus-Host Disease (GVHD). Some patients may reach a point where the side effects of the bone marrow transplant may outweigh the problems associated with MDS disease,. Therefore, the decision to undergo Bone Marrow Transplantation should be made after thorough discussions with the doctor and family, taking into account all aspects of the patient's condition and prognosis.

Hypocellular MDS is a rare type of Myelodysplastic Syndrome. For this condition, a drug called ATG (Anti-Thymocyte Globulin) is used as a treatment. While ATG can be expensive, it is considered less dangerous than a bone marrow transplant. Along with ATG, Cyclosporine is given as part of the treatment.

Decitabine or Azacytidine cycles, commonly used in other types of MDS, do not typically cause significant side effects. However, a major side effect can be a decrease in blood cell counts. In such cases, the duration of cycles is extended to 35 or 42 days instead of the standard 28 days.

Patients with MDS do not require any special diet. However, to prevent infections through food, it is recommended to consume only cooked food and boiled water. If any symptoms like fever, vomiting, abdominal pain, or diarrhea occur, the patient should seek immediate medical attention and consider receiving antibiotic injections if necessary. To minimize the risk of infections, the patient should avoid contact with infected individuals and large crowds. Maintaining good hygiene, such as daily bathing, is important.

It's essential to know that MDS is not a contagious disease, so there is no problem if the patient interacts with family members. The disease is not hereditary either.

Ongoing efforts to develop new drugs for the treatment of MDS are underway, and the effects of these drugs are tested in clinical trials. If the opportunity arises to participate in clinical

trials, patients should consider taking advantage of it without hesitation.

For any additional information about MDS beyond what is provided here, it is best to contact the patient's healthcare team. They can offer personalized guidance and address any specific concerns related to the individual's condition and treatment plan.

Dr. Girish Kamat MD, DNB (Hematology)
Professor,
Department of Hematology,
SDM College of Medical Sciences and Hospital,
Sri Dharmasthala Manjunatheshwara University,
Dharwad- 580008